Ashburn, VA – March 13, 2018 – Aperiomics, a company that helps doctors and their patients worldwide solve difficult medical cases and limit the use of antibiotics, has again been named among the DC region’s most innovative companies.
Aperiomics is a finalist in The Greater Washington Innovation Awards presented by the Northern Virginia Chamber of Commerce. The company was named “Life Sciences Innovator of the Year” in 2016 and this is its third straight year as a finalist.
According to the chamber, the competition “celebrates the people and organizations who introduce new methods, ideas and products to improve our lives and challenge the status quo. Their innovations create new consumers and markets, and ultimately transform the way we do business.” Winners will be announced at The Hamilton in Washington D.C. on April 4.
Aperiomics is the only company of its kind and scope in the world. Its proprietary technology identifies every bacteria, virus, fungus and parasite (the causes of infection), in a single test through deep shotgun metagenomic sequencing of the DNA in patients’ biological samples.
Company CEO Dr. Crystal Icenhour, an expert in infectious disease diagnostics, said, “This cutting-edge technology helps patients get well and saves substantial healthcare expenditures. Given the concentration of health-related companies in our region, all of us at Aperiomics are excited and honored to be among the finalists. This is a strong vote of confidence of our place in the region’s business community and in the work we do for doctors and their patients.”
Aperiomics is the only company identifying every bacteria, DNA virus, fungi and parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through deep shotgun metagenomic sequencing of the DNA in any sample (patient, environmental, etc.). The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about our successes in helping others. Aperiomics is supported by the National Science Foundation. It was named Life Sciences Innovator of the Year in 2016 and a finalist in the 2018 Greater Washington Innovation Awards. For more information, visit www.aperiomics.com or call (703) 229-0406.